Breaking AI & Tech News Analyzed

Helen DeWitt, the American author of "The Last Samurai," announced she turned down the Windham‑Campbell writing prize—a $175,000 (£130,000) award—after learning that acceptance hinged on a series of promotional commitments.In a personal blog and a thread on X, DeWitt explained that the prize required her to attend a festival, appear on a podcast, and take part in a six‑ to eight‑hour filming session for a promotional video.She disclosed that, at the time, she was "close to breakdown" due to a cascade of professional and personal challenges, making the additional obligations impossible to meet.DeWitt likened the situation to the early‑career expectations of writers such as Thomas Pynchon or Cormac McCarthy, noting that the demands would be "horrifying" for anyone in a similar position.Correspondence with prize director Michael Kelleher showed limited flexibility: while he agreed to drop the podcast requirement, he maintained that DeWitt herself had to appear in the video, rejecting her proposal to feature other writers or her husband instead.Ultimately, DeWitt wrote that she must "regretfully decline to accept the prize on the specified terms," and the award was forfeited.The Windham‑Campbell prizes, founded in 2013 from the bequest of novelist Donald Windham, are intended to be "life‑changing" recognitions. This year’s recipients include British novelist Gwendoline Riley, and winners are selected confidentially.DeWitt argued that a prize structure that excludes writers unable to meet extra promotional duties contradicts the spirit of its generous founders. Kelleher responded that participation is optional and that the organization respects any decision not to engage, emphasizing the "power of literature to connect us all."

Liverpool's Champions League hopes were dealt a significant blow as they were outplayed by PSG in a disappointing performance, leaving them to face a tough second leg. The Reds created almost nothing throughout the game and were fortunate to escape with only a two-goal deficit.In a dramatic turn of events at Barcelona, Pau Cubarsi's red card and a stunning Julián Alvarez free-kick handed Atlético Madrid a crucial advantage in their quarter-final tie. This pivotal moment shifted the momentum entirely in favor of Atlético, setting up an intense second leg in Madrid.The podcast also previews huge Premier League games at both the top and bottom of the table, discusses Fifa's new partnership, and answers listener questions.

In a thrilling Champions League matchup, Arsenal claimed a crucial victory in Lisbon, with Kai Havertz scoring the winning goal in injury time after Gabriel Martinelli drew the defense. This win comes after Arsenal lost their previous two matches, making it a significant turnaround for the team.Elsewhere, Bayern Munich secured a win at the Bernabéu, with Trent Alexander-Arnold's perfect ball setting up Kylian Mbappé's goal. This result keeps the tie very much alive, with both teams still in contention.The podcast also discusses a big Easter of Football League action and pays tribute to Aaron Ramsey. Listeners can find Football Weekly on various platforms, including Instagram, TikTok, and YouTube.

Joe Eszterhas, the swaggering pitchman of 80s and 90s Hollywood, has lived a life of excess and creativity. He wrote hits like Jagged Edge and co-scripted Flashdance, earning a then-record $3m for his Basic Instinct screenplay.Eszterhas's life story is a harrowing, rollicking immigrant's tale that whisks its hero from his birth in war-torn Hungary through the refugee camps of Allied-occupied Austria to the US rust belt. He covered the Kent State massacre as a cub reporter and interviewed Charles Manson in prison.Now 81, Eszterhas is plotting a Hollywood comeback with a rebooted Basic Instinct. He received a reported $2m from Amazon MGM studios for his script and stands to make a further $2m if and when it is filmed. The new story juggles copycat serial killers with elements of the supernatural.Eszterhas has always relished a good public scrap, and his reboot is described as anti-woke. This has sparked concerns that he may be co-opted and become a political football. However, Eszterhas insists that he is not afraid of controversy and sexuality.Despite his past struggles with drinking and drugs, Eszterhas has been clean and sober for decades. He has written a 750-page memoir, Hollywood Animal, and told his Tinseltown war stories on a recent multi-part media podcast, Ugly, Irresponsible, & Childish.

Kemiah Bob, a Texan standup comedian, has been working tirelessly to create a space for femmes of colour in comedy. In 2018, Bob launched FOC It Up, a comedy club that has grown into a platform for numerous comedians. The club has hosted mixed-bill comedy nights, a podcast, and shows at the Edinburgh fringe.Bob's latest venture, FOC Fest, is a full-day celebration of comedy, workshops, masterclasses, and networking opportunities, culminating in a comedy show at Soho Theatre in London on April 18. The event aims to provide a safe space for femmes of colour to showcase their talents and for industry professionals to network.The festival features sessions such as a standup masterclass for trans and queer people, a workshop on navigating difficult emotions through comedy, and industry panels with guests including Nana Hughes and Julia McKenzie. While the workshops are open to everyone, Bob encourages white audience members to 'check their privilege at the door'.Despite the challenges of securing funding, Bob remains committed to creating a platform for underrepresented voices in comedy. The goal is for FOC Fest to become an international institution, showcasing talent from around the world and providing support for comedians to fund their own work.FOC Fest is a testament to Bob's dedication to promoting diversity and inclusivity in the comedy industry. With its unique blend of comedy, workshops, and networking opportunities, this event is set to make a lasting impact on the comedy world.

The U.S. Supreme Court issued a decision on Monday that removes a procedural obstacle, allowing the Justice Department to proceed with a motion to dismiss the criminal case against Steve Bannon. The case stems from a 2022 conviction on two counts of contempt of Congress for refusing to comply with a subpoena issued by the House committee investigating the January 6, 2021 Capitol attack. Bannon, a former chief strategist for President Donald Trump, served a four‑month prison term after the conviction. Although the sentence is now complete, the Justice Department argues that dismissing the case is "in the interests of justice" and has asked the high court to overturn the lower‑court ruling that kept the conviction in place. Attorney Evan Corcoran, representing Bannon, welcomed the development, stating, "It has been one battle after another for five years, but today the Supreme Court vacated an unjust conviction, reaffirming that politics and prosecution don’t mix." A dismissal would expunge Bannon’s conviction from the record, but the practical impact is minimal because he has already completed his sentence. The move is part of a broader pattern of the Justice Department taking actions that benefit allies of the former president since his return to office in 2024. Background: Bannon, now 72, was a key adviser to Trump’s 2016 campaign and served as the White House’s chief strategist in 2017. After a brief fallout, he reconciled with Trump and was released from Danbury federal prison a week before Trump’s victory over Kamala Harris in the 2024 presidential election. Upon release, Bannon declared himself “far from broken” and resumed hosting his "War Room" podcast, continuing to promote the “America First” brand of right‑wing populism. Legal arguments raised by Bannon’s team centered on claims of executive privilege and challenges to the congressional committee’s authority to issue the subpoena. The case unfolds against a backdrop of numerous pardons granted by Trump to individuals convicted in connection with the Capitol riot and other allies facing charges related to attempts to overturn the 2020 election.

The Uncanny podcast has evolved from a simple Radio 4 paranormal investigations podcast to a global franchise, including live stage shows, a TV series, and a US spinoff.Host Danny Robins, known as the 'high priest of the paranormal,' has captivated audiences with spine-tingling stories, dissecting each tale with parapsychologists Evelyn Hollow and Ciarán O’Keeffe.The podcast's success can be attributed to its unique format, featuring 8 million+ downloads within two years, and its expansion into various media, including a new YouTube channel focused on classic cold cases.The Uncanny community has grown to millions, with fans bonding over shared experiences and discussing cases on social media, showcasing the power of prestige paranormal storytelling.Experts attribute the podcast's appeal to its blend of drama and true crime elements, making it a detective story that keeps listeners engaged and curious.As Uncanny continues to grow, with plans for international tours, new TV series, and conventions, its impact on popular culture and the paranormal genre is undeniable, reflecting our society's increasing fascination with the supernatural.

The Guardian’s weekly podcast roundup highlights a varied selection of new audio series, offering listeners everything from light‑hearted celebrity banter to hard‑hitting investigative journalism.Funny You Ask – In a delightfully candid moment, Mindy Kaling exclaims, “Oh, this is a quizshow?!” upon hearing Ike Barinholtz’s latest podcast, which blends trivia with rambling conversation about topics as eclectic as Chevy Chase and New Jersey Italian cuisine. The show positions itself as a breezy, low‑stakes alternative to the crowded celebrity‑interview market.Assume Nothing: What Happened to Mary Glasgow? – Host Nathan Edgar revisits the 1991 tragedy at Stradreagh mental hospital, where nursing assistant Mary Glasgow died after a patient altercation. Through interviews with Glasgow’s daughter Emma, the series treats the case as both a detective narrative and a memorial, probing whether the incident was an isolated mishap or a symptom of systemic failures.Single Ladies in Your Area – Comedians Amy Gledhill and Harriet Kemsley continue their third series, a witty exploration of 30‑something singledom. Recent guests have included Jameela Jamil and Catherine Bohart, who discuss topics ranging from “mean flirting” to the quirks of a “lesbian louche life.”The Overturn – Partnering with the Future Justice Project charity, Marnie Duke examines potential wrongful convictions, notably the case of former sub‑postmaster Robin Garbutt, imprisoned for his wife’s murder. The series asks whether the broader Post Office scandal could cast doubt on the prosecution’s narrative.Amityvilleville – Host Alex Goldman (of Hyperfixed and Reply All) teams up with Vice writer Caroline Thompson to watch all 91 films inspired by the Amityville haunting, beginning with the 1979 classic The Amityville Horror. Their commentary blends humor with genuine enthusiasm for the genre’s most bizarre entries.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”